Cytotoxic effects of coumarin substituted benzimidazolium salts against human prostate and ovarian cancer cells

  • Mert Olgun KarataşEmail author
  • Suat Tekin
  • Bülent Alici
  • Süleyman Sandal
Regular Article


Coumarin and benzimidazole derivatives have individual biological activities including anticancer. In this study, we aimed to synthesize coumarin-benzimidazole hybrids in order to investigate their anticancer properties. For this purpose, six 6-substituted-4-chloromethylene coumarin derivatives were synthesized. Sixteen coumarin substituted benzimidazolium chlorides were synthesized by the reaction of 4-chloromethylene coumarin and N-benzylbenzimidazole derivatives. All of the synthesized compounds were characterized by \(^{1}\hbox {H}\) and \(^{13}\hbox {C}\) NMR, IR spectroscopic techniques and elemental analyses. Cytotoxicities of all compounds were tested by [3-(4,5-dimethylthiazole)-2-yl]-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay against human prostate (PC-3) and ovarian (A2780) cancer cells. All compounds performed significant cytotoxicities at \(100\,\upmu \hbox {M}\) against both cancer cell lines. Moreover, some compounds performed significant activities at \(1\,\upmu \hbox {M}\) against both cancer cell lines and the obtained results suggest that this type of compounds are promising candidates for the treatment of human prostate and ovarian cancers.

Graphic abstract

Six 4-chloromethylenecoumarin derivatives and sixteen coumarin substituted benzimidazolium chlorides were synthesized and characterized. Cytotoxic properties of all compounds were tested against human prostate and ovarian cancer cell lines.


Benzimidazole benzimidazolium salt coumarin cytotoxicity 



The authors report no conflicts of interest. The authors are alone responsible for the content and writing of the paper.

Supplementary material

12039_2019_1647_MOESM1_ESM.pdf (1.4 mb)
Supplementary material 1 (pdf 1392 KB)


  1. 1.
    Daly A K 2013 Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms Arch. Toxicol. 87 407CrossRefGoogle Scholar
  2. 2.
    Yu D, Suzuki M, Xie L, Morris-Natschke S L and Lee K H 2003 Recent progress in the development of coumarin derivatives as potent anti-HIV agents Med. Res. Rev. 23 322CrossRefGoogle Scholar
  3. 3.
    Maresca A, Temperini C, Vu H, Pham N B, Poulsen S A, Scozzafava A, Quinn R J and Supuran C T 2009 Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors J. Am. Chem. Soc. 131 3057CrossRefGoogle Scholar
  4. 4.
    Zhao H, Donelly A C, Kusuma B R, Brandt G E L, Brown D, Rajewski R A, Vielhauer G, Holzbeierlein J, Cohen M S and Blagg B S J 2011 Engineering an antibiotic to fight cancer: optimization of the Novobiocin scaffold to produce anti-proliferative agents J. Med. Chem. 54 3839CrossRefGoogle Scholar
  5. 5.
    Emami S and Dadashpour S 2015 Current developments of coumarin-based anti-cancer agents in medicinal chemistry Eur. J. Med. Chem. 102 611CrossRefGoogle Scholar
  6. 6.
    Sandhu S, Bansal Y, Silakari O and Bansal G 2014 Coumarin hybrids as novel therapeutic agents Bioorg. Med. Chem. 22 3806CrossRefGoogle Scholar
  7. 7.
    Barot K P, Jain S V, Kremer L, Singh S and Ghate M D 2015 Recent advances and therapeutic journey of coumarins: current status and perspectives Med. Chem. Res. 24 2771CrossRefGoogle Scholar
  8. 8.
    Barker H A, Smyth R D, Weissbach H, Toohey J I, Ladd J N and Volcani B E 1960 Isolation and properties of crystalline cobamide coenzymes containing benzimidazole or 5,6-dimethylbenzimidazole J. Biol. Chem. 253 480Google Scholar
  9. 9.
    Gaba M and Mohan C 2016 Development of drug-based imidazole and benzimidazole bioactive heterocycles: recent advances and future directions Med. Chem. Res. 25 173CrossRefGoogle Scholar
  10. 10.
    Shrivastava N, Naim M J, Alan M J, Nawaz F, Ahmed S and Alam O 2017 Benzimidazole scaffold as anticancer agent: synthetic approaches and structure–activity relationship Arch. Pharm. Chem. Life Sci. 350 e1700040CrossRefGoogle Scholar
  11. 11.
    Yadav G and Ganguly S 2015 Structure activity relationship (SAR) study of benzimidazole scaffold for different activities: a mini-review Eur. J. Med. Chem. 97 419CrossRefGoogle Scholar
  12. 12.
    Gravel J and Schmitzer A R 2017 Imidazolium and benzimidazolium-containing compounds: from simple toxic salts to highly bioactive drugs Org. Biomol. Chem. 15 1051CrossRefGoogle Scholar
  13. 13.
    Elie C R, David G and Schmitzer A R 2015 Strong antibacterial properties of anion transporters: a result of depolarization and weakening of the bacterial membrane J. Med. Chem. 58 2358CrossRefGoogle Scholar
  14. 14.
    Liu L X, Wang X Q, Zhou B, Yang L J, Li Y, Zhang H B and Yang X D 2015 Synthesis and antitumor activity of novel N-substituted carbazole imidazolium salt derivatives Sci. Rep. 5 13101CrossRefGoogle Scholar
  15. 15.
    Karataş M O, Alıcı B, Çetinkaya E, Bilen Ç, Gençer N and Arslan O 2014 Synthesis, characterization and tyrosinase inhibitory properties of benzimidazole derivatives Russ. J. Bioorg. Chem. 40 46CrossRefGoogle Scholar
  16. 16.
    Karataş M O, Uslu H, Sarı S, Alagöz M A, Karakurt A, Alıcı B, Bilen Ç, Yavuz E, Gençer N and Arslan O 2016 Coumarin or benzoxazinone based novel carbonic anhydrase inhibitors: synthesis, molecular docking and anticonvulsant studies J. Enzyme Inhib. Med. Chem. 31 760CrossRefGoogle Scholar
  17. 17.
    Karataş M O, Uslu H, Alıcı B, Gökçe B, Gençer N, Arslan O, Arslan N B and Özdemir N 2016 Functionalized imidazolium and benzimidazolium salts as paraoxonase 1 inhibitors: synthesis, characterization and molecular docking studies Bioorg. Med. Chem. 24 1392CrossRefGoogle Scholar
  18. 18.
    Erdemir F, Celepci D B, Aktaş A, Taslimi P, Gök Y, Karabıyık H and Gülçin İ 2018 2-Hydroxyethyl substituted NHC precursors: synthesis, characterization, crystal structure and carbonic anhydrase, \(\alpha \)-glycosidase, butyrylcholinesterase, and acetylcholinesterase inhibitory properties J. Mol. Struct. 1155 797CrossRefGoogle Scholar
  19. 19.
    Hosamani K M, Reddy D S and Devarajegowda H C 2015 Microwave-assisted synthesis of new fluorinated coumarin-pyrimidine hybrids as potent anticancer agents, their DNA cleavage and X-ray crystal studies RSC Adv. 5 11261CrossRefGoogle Scholar
  20. 20.
    Wei H, Ruan J and Zhang X 2016 Coumarin-chalcone hybrids: promising agents with diverse pharmacological properties RSC Adv. 6 10846CrossRefGoogle Scholar
  21. 21.
    Samundeeswari S, Kulkarni M V, Joshi S D, Dixit S R Jayakumar S and Ezhilarasi R M 2016 Synthesis and human anticancer cell line studies of coumarin-b-carboline hybrids as possible antimitotic agents ChemistrySelect 1 5019CrossRefGoogle Scholar
  22. 22.
    Pathoor R and Bahulayan D 2018 MCR-click synthesis, molecular docking and cytotoxicity evaluation of a new series of indole-triazole-coumarin hybrid peptidomimetics New J. Chem. 42 1810CrossRefGoogle Scholar
  23. 23.
    Yu H, Hou Z, Tian Y, Mou Y and Guo C 2018 Design, synthesis, cytotoxicity and mechanism of novel dihydroartemisinin-coumarin hybrids as potential anticancer agents Eur. J. Med. Chem. 151 434CrossRefGoogle Scholar
  24. 24.
    Ayati A, Bakhshaiesh T D, Moghimi S, Esmaeili R, Majidzadeh-A K, Safavi K, Firoozpour L, Emami S and Foroumadi A 2018 Synthesis and biological evaluation of new coumarins bearing 2,4-diaminothiazole-5-carbonyl moiety Eur. J. Med. Chem. 155 483CrossRefGoogle Scholar
  25. 25.
    Lingaraju G S, Balaji K S, Jayarama S, Anil S M, Kiran K R and Sadashiva M R 2018 Synthesis of new coumarin tethered isoxazolines as potential anticancer agents Bioorg. Med. Chem. Lett. 28 3606CrossRefGoogle Scholar
  26. 26.
    Singla P, Luxami V and Paul K 2015 Triazine-benzimidazole hybrids: anticancer activity, DNA interaction and dihydrofolate reductase inhibitors Bioorg. Med. Chem. 23 1691CrossRefGoogle Scholar
  27. 27.
    Reddy N B, Burra V R, Ravindransth L K, Kumar V N, Sreenivasulu R and Sadanandan P 2016 Synthesis and biological evaluation of benzimidazole fused ellipticine derivatives as anticancer agents Monatsh. Chem. 147 599CrossRefGoogle Scholar
  28. 28.
    Lukowska-Chojnacka E, Winska P, Wielechowska M and Bretner M 2016 Synthesis of polybrominated benzimidazole and benzotriazole derivatives containing a tetrazole ring and their cytotoxic activity Monatsh. Chem. 147 1789CrossRefGoogle Scholar
  29. 29.
    Koronkiewicz M, Chilmonczyk Z, Kazimerczuk Z and Orzesko A 2018 Deoxynucleosides with benzimidazoles as a plycome moiety are potent anticancer activity Eur. J. Pharmacol. 820 146CrossRefGoogle Scholar
  30. 30.
    Baig M F, Nayak V L, Budaganaboyina P, Mullagiri K, Sunkari S, Gour J and Kamal A 2018 Synthesis and biological evaluation of imidazo[2,1-\(b\)]thiazole-benzimidazole conjıgates as microtubule-targeting agents Bioorg. Chem. 77 515CrossRefGoogle Scholar
  31. 31.
    Wang Z, Deng X, Xiong S, Xiong R, Liu J, Zou L, Lei X, Cao X, Xie Z, Chen Y, Liu Y, Zhang X and Tang G 2018 Desing, synthesis and biological evaluation of chrysin benzimidazole derivatives as potential anticancer agents Nat. Prod. Res. 32 2900CrossRefGoogle Scholar
  32. 32.
    Hwu J R, Singha R, Hung S C, Chang Y H, Das A R, Vliegen I, Clercq E D and Neyts J 2008 Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents Antivir. Res. 77 157CrossRefGoogle Scholar
  33. 33.
    Neyts J, Clercq E D, Singha R, Chang Y H, Das A R, Chakraborty S K, Hong S C, Tsay S C, Hsu M H and Hwu J R 2009 Structure-activity relationship of new anti-hepatitis C virus agents: heterobicycle-coumarin conjugates J. Med. Chem. 52 1486CrossRefGoogle Scholar
  34. 34.
    Paul K, Bindal S and Luxami V 2013 Synthesis of new conjugated coumarin-benzimidazole hybrids and their anticancer activity Bioorg. Med. Chem. Lett. 23 3667CrossRefGoogle Scholar
  35. 35.
    Holiyachi M, Shastri S D, Chougala B M, Shastri L A, Joshi S D, Dixit S R, Nagarajaiah H and Sunagar V A 2016 Design, synthesis and structure-activity relationship study of coumarin benzimidazole hybrid as potent antibacterial and anticancer agents ChemistrySelect 1 4638CrossRefGoogle Scholar
  36. 36.
    Frasinyuk M S, Vinogradova V I, Bondarenko S P and Khilya V P 2007 Synthesis of cytisine derivatives of coumarins Chem. Nat. Compd. 43 590CrossRefGoogle Scholar
  37. 37.
    Kolocouris N, Foscolos G B, Kolocouris A, Marakos P, Pouli N, Fytas G, Ikeda S and Clercq E D 1994 Synthesis and antiviral activity evaluation of some aminoadamantane derivatives J. Med. Chem. 37 2896CrossRefGoogle Scholar
  38. 38.
    Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay J. Immunol. Methods 65 55CrossRefGoogle Scholar
  39. 39.
    Görgülü A O, Koran K, Özen F, Tekin S and Sandal S 2015 Synthesis, structural characterization and anti-carcinogenic activity of new cyclotriphosphazenes containing dioxybiphenyl and chalcone J. Mol. Struct. 1087 1CrossRefGoogle Scholar
  40. 40.
    Mosmann T R, Cherwinski H, Bond M W, Giedlin M A and Coffman R L 1986 Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins J. Immunol. 136 2348PubMedGoogle Scholar
  41. 41.
    Karataş M O, Olgundeniz B, Günal S, Özdemir İ, Alıcı B and Çetinkaya E 2016 Synthesis, characterization and antimicrobial activities of novel silver(I) complexes with coumarin substituted N-heterocyclic carbene ligands Bioorg. Med. Chem. 24 643CrossRefGoogle Scholar
  42. 42.
    Sato A, Itcho N, Ishiguro H, Okamoto D, Kobayashi N, Kawai K, Kasai H, Kurioka D, Uemura H, Kubota Y and Watanabe M 2013 Magnetic nanoparticles of \(\text{ Fe }_{3}\text{ O }_{4}\) enhance docetaxel-induced prostate cancer cell death Int. J. Nanomed. 8 3151Google Scholar
  43. 43.
    Çekirdek S, Yaşar S and Özdemir İ 2014 Palladium(II)-N-heterocyclic carbene complexes: synthesis, characterization and catalytic application Appl. Organomet. Chem. 28 423CrossRefGoogle Scholar
  44. 44.
    Minematsu T, Iwai M, Sugimoto K, Shirai N, Nakahara T, Usui T and Kamimura H 2009 Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1\(H\)-naphtho[2,3-\(d\)]imidazolium bromide (YM155 monobromide), a novel small-molecule Survivin suppressant, into human solid tumor and Lymphoma cells Drug Metab. Dispos. 37 619CrossRefGoogle Scholar
  45. 45.
    Lambrecht F Y, Ocakoğlu K, Colak S G, Ersoz O A and Er O 2017 Synthesis and investigation of anticancer potential of radiolabeled naphthalane monoamide bearing imidazolium salt Chem. Biol. Drug Des. 90 141CrossRefGoogle Scholar
  46. 46.
    Wright B D, Deblock M C, Wagers P O, Duah E, Robishaw N K, Shelton K L, Southerland M R, DeBord M A, Kersten K M, McDonald L J, Stiel J A, Panzner M J, Tessier C A, Paruchuri S and Youngs W J 2015 Anti-tumor activity of lipophilic imidazolium salts on select NSCLC cell lines Med. Chem. Res. 24 2838CrossRefGoogle Scholar
  47. 47.
    Zhang C B, Liu Y, Liu Z F, Duan S Z, Li M Y, Chen W, Li Y, Zhang H B and Yang X D 2017 Synthesis and cytotoxic activity of novel tetrahydrobenzodifuran imidazolium salt derivatives Bioorg. Med. Chem. Lett. 27 1808CrossRefGoogle Scholar

Copyright information

© Indian Academy of Sciences 2019

Authors and Affiliations

  1. 1.Department of Chemistry, Faculty of Scienceİnönü UniversityMalatyaTurkey
  2. 2.Department of Physiology, Faculty of Medicineİnönü UniversityMalatyaTurkey

Personalised recommendations